Compound 1115
Identifiers
- Canonical SMILES:
CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(cc1S(=O)(=O)C(F)(F)F)S(=O)(=O)Nc1ncnc2CN(CCc12)C1CCN(Cc2ccccc2-c2ccccc2Cl)CC1
- IUPAC name:
N-[7-[1-[[2-(2-chlorophenyl)phenyl]methyl]piperidin-4-yl]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]-4-[[(2R)-4-(dimethylamino)-1-phenylsulfanylbutan-2-yl]amino]-3-(trifluoromethylsulfonyl)benzenesulfonamide
- InChi:
InChI=1S/C44H49ClF3N7O4S3/c1-53(2)22-18-32(29-60-34-11-4-3-5-12-34)51-40-17-16-35(26-42(40)61(56,57)44(46,47)48)62(58,59)52-43-38-21-25-55(28-41(38)49-30-50-43)33-19-23-54(24-20-33)27-31-10-6-7-13-36(31)37-14-8-9-15-39(37)45/h3-17,26,30,32-33,51H,18-25,27-29H2,1-2H3,(H,49,50,52)/t32-/m1/s1
- InChiKey:
XIFJKHNOFQWWQU-JGCGQSQUSA-N
External links
![]() 51042648 |
External search
![]() |
![]() |
![]() |
![]() |
![]() |
Bibliography (1)
Publication | Name |
---|---|
Karen Miller-Moslin, Bakary-Barry Toure, Michael Scott Visser, Naeem Yusuff, Novartis Ag. . Sulfonamides as inhibitors of bcl-2 family proteins for the treatment of cancer None. | 98 |
Pharmacological data
Biochemical tests | Cellular tests | PK tests | Cytotoxicity tests |
---|---|---|---|
1 | 0 | 0 | 0 |
Targets
PPI family | Best activity | Diseases | MMoA |
---|---|---|---|
BCL2-Like / BAX | 7.44 | cancer | Inhibition |
Physicochemical filters
Descriptor | Lipinski's RO5 | Veber | Pfizer's 3/75 | |
---|---|---|---|---|
Compliance | ||||
MW | 927.26 g/mol | |||
HBA | 11 | |||
HBD | 2 | |||
HBA + HBD | 13 | |||
AlogP | 6.45 | |||
TPSA | 127.84 | |||
RB | 16 |
Radar chart
PCA : iPPI-DB chemical space
PCA : Correlation circle
Efficiencies: iPPI-DB biplot LE versus LLE
Summary
Bibliographic ressources | Biochemical tests | Cellular tests | PK tests | Cytotoxicity tests |
---|---|---|---|---|
1 | 1 | 0 | 0 | 0 |
Pharmacological data
Bibliography | Name | Target | Competition | Assay type | Assay name | Cell line | Activity type | Activity |
---|---|---|---|---|---|---|---|---|
WO2011029842 | 98 | BCL2 P10415 |
|
Biochemical assay | Surface Plasmon Resonance | pIC50 (half maximal inhibitory concentration, -log10) | 7.44 |
Ta | Structure | Name | Drugbank ID |
---|---|---|---|
0.4811 | Navitoclax | DB12340 | |
0.3918 | N-{2-[6-(2,4-DIAMINO-6-ETHYLPYRIMIDIN-5-YL)-2,2-DIMETHYL-3-OXO-2,3-DIHYDRO-4H-1,4-BENZOTHIAZIN-4-YL]ETHYL}ACETAMIDE | DB06899 | |
0.3867 | GDC-0349 | DB13072 | |
0.3862 | Sulfaisodimidine | DB13283 | |
0.3715 | N-(2-(((5-CHLORO-2-PYRIDINYL)AMINO)SULFONYL)PHENYL)-4-(2-OXO-1(2H)-PYRIDINYL)BENZAMIDE | DB07800 | |
0.3669 | Presatovir | DB12165 | |
0.3546 | Quinupristin | DB01369 | |
0.3533 | Sparsentan | DB12548 | |
0.3509 | 5-(5-chloro-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine | DB07585 | |
0.3498 | Sulfametomidine | DB13485 | |
0.3467 | 4-[(5-CHLOROINDOL-2-YL)SULFONYL]-2-(2-METHYLPROPYL)-1-[[5-(PYRIDIN-4-YL)PYRIMIDIN-2-YL]CARBONYL]PIPERAZINE | DB04673 | |
0.3447 | PF-5190457 | DB14870 | |
0.3447 | 6-ethyl-5-[(2S)-1-(3-methoxypropyl)-2-phenyl-1,2,3,4-tetrahydroquinolin-7-yl]pyrimidine-2,4-diamine | DB08099 | |
0.3440 | 5-(2,3-dichlorophenyl)-N-(pyridin-4-ylmethyl)-3-thiocyanatopyrazolo[1,5-a]pyrimidin-7-amine | DB07065 | |
0.3435 | Tianeptine | DB09289 |